Christelle Remy‐Ziller

Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition

Patricia Kleinpeter, Laetitia Fend, Christine Thioudellet et al. · OncoImmunology · 2016 · 95 citations · Full text

Medicine, Cancer Biology, Oncology +17

Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment

Laetitia Fend, Christelle Remy‐Ziller, Johann Foloppe et al. · OncoImmunology · 2015 · 34 citations · Full text

Medicine, Immunology, Oncology +17

Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model

Christelle Remy‐Ziller, Christine Thioudellet, Julie Hortelano et al. · Human Vaccines & Immunotherapeutics · 2017 · 34 citations · Full text

Life Sciences, Immunology, Oncology +17

By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1

Patricia Kleinpeter, Christelle Remy‐Ziller, Eline Winter et al. · Journal of Virology · 2019 · 25 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

Immunological Characterization of a Modified Vaccinia Virus Ankara Vector Expressing the Human Papillomavirus 16 E1 Protein

Christelle Remy‐Ziller, Claire Germain, Anita Spindler et al. · Clinical and Vaccine Immunology · 2013 · 18 citations · Full text

Life Sciences, Immunology, Oncology +17